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Abstract: Zika Virus (ZIKV) and Dengue Virus (DENV) are related viruses of the Flavivirus genus
that cause significant disease in humans. Existing control measures have been ineffective at curbing
the increasing global incidence of infection for both viruses and they are therefore prime targets for
new vaccination strategies. Type-I interferon (IFN) responses are important in clearing viral infection
and for generating efficient adaptive immune responses towards infection and vaccination. However,
ZIKV and DENV have evolved multiple molecular mechanisms to evade type-I IFN production.
This review covers the molecular interactions, from detection to evasion, of these viruses with the
type-I IFN response. Additionally, we discuss how this knowledge can be exploited to improve the
design of new vaccine strategies.
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1. Introduction
Dengue Virus (DENV) and Zika Virus (ZIKV) are closely related viruses of the Flavivirus genus and
although most infections in humans are asymptomatic, both viruses can cause severe life threatening
or debilitating disease. DENV includes four serotypes (DENV-1-4) and collectively causes the greatest
disease burden of all flaviviruses, infecting more than 390 million people causing 21,000 deaths
annually [1]. Comparatively, ZIKV is mono-serotypic and causes far fewer deaths, but infection during
pregnancy can result in infection of the developing fetus, early pregnancy loss, or developmental and
neurological impairment in newborns [2]. The primary mode of ZIKV and DENV transmission is
via mosquitoes of the Aedes species. As a result of their shared vector, both viruses co-circulate in
tropical and sub-tropical regions of Africa, Asia and the Americas [3]. It is estimated that more than
one third of the world population lives in areas with high risk of DENV infection [4]. Worryingly, both
of these viruses have rapidly expanded their geographic range in recent years as a result of factors
such as climate change and globalization [5]. Currently, there are no specific antiviral treatments for
either infection despite DENV and ZIKV posing serious threats to human health and placing large
socio-economic burdens on many of the world’s most under-developed nations. To date there are
no approved vaccines for ZIKV, but several vaccine candidates are currently being investigated and
as of late 2019, the WHO listed 15 vaccine candidates in phase I/II clinical trials [6]. These include
DNA, RNA, recombinant protein, recombinant viral vector, and inactivated whole virus vaccines.
As for DENV, there is an approved vaccine (Dengvaxia®) developed by Sanofi Pasteur; however, it
is not recommended for children under 9 years of age and has been associated with safety concerns
due to its ability to increase the risk of severe disease in people who are seronegative when receiving
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vaccination [7]. Despite its limited applicability, Dengvaxia® generates immune responses against all
four serotypes and reduces the incidence of severe complications associated with DENV infection [8].
Development of specific, effective, and safe treatments and vaccines for the prevention of both ZIKV and
DENV requires understanding of their fundamental biology, pathogenesis, and molecular interactions
with the host immune response.
The type-I IFNs are produced in response to sensing viral infection within cells and act as a
crucial front-line defense against a broad range of viral pathogens [9]. Once produced and secreted by
infected cells these antiviral cytokines can act on the same cell or neighboring cells expressing their
cognate receptor to initiate signaling that leads to the production of hundreds of interferon stimulated
genes (ISGs) [10]. These ISGs carry out a range of direct antiviral, regulatory or immunomodulatory
functions giving rise to an antiviral state within host cells and tissues [11]. Importantly this IFN
response shapes aspects of the adaptive immune response to viruses, leading to improved cell mediated
and humoral responses [12]. As a result, the IFN response is a barrier that viruses must overcome to
cause infection, replicate, and spread. Not surprisingly, because of this strong selective pressure many
viruses have evolved mechanisms to counteract IFN responses, allowing them to gain a foothold and
cause infection. For example, flaviviruses such as ZIKV and DENV have evolved a complex array of
molecular interactions with the host innate immune response to undermine both the production and
downstream signaling of IFNs.
This review aims to summarize the current knowledge of the molecular interactions between
ZIKV and DENV with the type-I IFN response. Furthermore, we discuss how this knowledge can be
exploited in the development of safe and effective vaccines.
2. DENV/ZIKV Virology and Lifecycle
The design of new therapeutics and vaccines is underpinned by understanding the fundamental
biology and lifecycle of the virus. In the following section we explain the relevant aspects of Flavivirus
virology and lifecycle.
2.1. Phylogeny and Genome Structure
The Flavivirus are a genus of primarily arthropod borne, enveloped, non-segmented positive-sense
single-stranded RNA (+ssRNA) viruses that include several major human pathogens such as Yellow
Fever Virus (YFV), Japanese Encephalitis Virus (JEV), West Nile Virus (WNV), DENV and ZIKV.
Within the Flavivirus genus DENV and ZIKV are closely related, sharing on average 55% amino acid
identity [13]. Both the +ssRNA genomes for DENV and ZIKV are approximately 11kb in size, are
flanked by 5′ and 3′ untranslated regions (UTRs) and contain a central open reading frame (ORF)
encoding the structural (Capsid (C), pre-Membrane (prM) and Envelope (E)) and non-structural (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5) viral proteins (Figure 1). The 5′ end of the genome terminates in
a type-I cap, mimicking the structure of host mRNA [14]. Both the 5′ and 3′ UTR’s are predicted to
form extensive RNA secondary structures that are conserved among flaviviruses [15]. These RNA
structures are critical for genome replication and also evasion of host immune responses [16]. In general,
the structural proteins are involved with infectious particle (virion) production, virus attachment,
entry and uncoating. The NS proteins play various roles in the intracellular aspects of the virus
lifecycle, including genome replication, translation, processing of the viral polyprotein, membrane
rearrangements, virion assembly, and evasion of the innate immune response.
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Figure 1. A schematic representation of the Flavivirus genome. The genome is a single positive-sense
single-stranded RNA (+ssRNA) molecule that is roughly 11 kb in size, capped at the 5′ terminus and
flanked by 5′ and 3′ untranslated regions (UTR). The central open reading frame (ORF) encodes a
polyprotein that is cleaved into individual structural and non-structural (NS) viral proteins, the text
below lists some of their known functions as reviewed in [17].
2.2. Lifecycle
As closely related flaviviruses, ZIKV and DENV share many aspects of their lifecycle within host
cells. The Flavivirus lifecycle is carried out in several stages: Attachment, entry, fusion and uncoating,
initial translation of the viral proteins, generation of the replication complex and replication of new
viral genomes, assembly, maturation, and egress [18], summarized in Figure 2.
Figure 2. Stages of the Flavivirus lifecycle. (1) Attachment and receptor-mediated endocytosis. (2) Membrane
fusion and particle disassembly. (3) Genome release into the cytoplasm. (4) Polyprotein translation.
(5) Replication complex (RC) formation and genome replication. (6) Virion packaging. (7) Transportation
through the trans-Golgi network and virion maturation. (8) Virion egress by exocytosis.
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Initially virions attach to host cells via interactions with host cell surface receptors to gain entry to
the cell. Virion attachment and entry involves multiple host surface receptors [19,20]. Some of the
known attachment factors for DENV and ZIKV include glycosaminoglycans (GAGs), such as heparan
sulphate [19], C-type Lectin Receptors (CLRs) such as DC-SIGN [21] and members of the TIM (TIM1,
TIM3, and TIM4) and TAM (Tyro3, Axl, and Mer) family of receptors [21,22]. Following attachment,
the virion enters the host cell via clathrin-mediated endocytosis [19]. The clathrin-coated vesicle is
processed to form an early endosome, these are then increasingly acidified to form late-endosomes [23].
The low pH environment of the late-endosome drives conformational changes in the E protein present
on the virion surface leading to membrane fusion, uncoating and release of the +ssRNA genome into
the cytoplasm [18]. In the cytosol, viral replication is initiated by direct translation of the +ssRNA by
the host ribosome machinery that recognizes the type-I cap in the 5′ UTR [18]. The ORF is translated
as a single multi-pass transmembrane polyprotein imbedded into the endoplasmic reticulum (ER)
membrane. Following and during translation, the polyprotein is cleaved by host and viral proteases
(NS3) to liberate the individual viral proteins [15]. Together, multiple NS proteins interact with host
factors to induce changes in the structure of the ER membranes to generate replication organelles or
“vesicle packets” that house the viral replication complex (RC) [24]. The RC acts to concentrate viral and
host proteins that are essential for viral genome replication and also functions to hide the replicating
viral RNA from innate immune detection [24,25]. Following formation of the RC, the +ssRNA genome
is copied through a -ssRNA intermediate by the NS5 RNA dependent RNA polymerase (RdRp) in
coordination with other essential host and viral factors. The progeny genomes are capped by the NS5
methyl-transferase (MTase) domain and exit the vesicle packets through the vesicle pore where a single
+ssRNA copy interacts with multiple copies of the C protein to form the nucleocapsid [24]. Next, this
nucleoprotein complex buds into the ER-derived membrane imbedded with viral prM–E protein
heterodimers that coat the newly enveloped immature virion [18,26]. After entering the ER lumen, the
immature Flavivirus particle is shuttled through the secretory pathway. Here the virion undergoes
maturation involving the acid-induced rearrangement of E protein and subsequent cleavage of the
prM protein by furin into the mature M protein, forming a smooth outer coat [27]. Interestingly, some
immature prM also remains on the surface of virions [28] and during DENV infection, heterotypic
cross-reactive antibodies raised against prM promote antibody-dependent enhancement of severe
dengue disease [29] as reviewed in [30]. After maturation, new virions are released from the host cell
by exocytosis [26].
Importantly, the intracellular Flavivirus lifecycle is vulnerable to detection and inhibition by the
innate immune response. As a result, DENV and ZIKV have evolved subterfuge strategies to avoid
detection or prevent the actions of the innate immune response.
3. The Innate Immune Response to RNA Viruses
The innate immune response is the first line of defense against invading viral pathogens. This arm
of the immune system generates a rapid, non-specific response aiming to control infection. The innate
immune response also plays a crucial role in establishing adaptive immune responses, leading to
pathogen specific and long-lasting immunological memory [31]. In general, the innate immune
response is initiated by recognition of microbial components or pathogen associated molecular patterns
(PAMPs) that accumulate during infection. PAMPs bind to host germline encoded pattern recognition
receptors (PRRs) on the cell surface, within endosomes or in the cytoplasm, leading to recognition
leads to activation of complex signaling pathways and the upregulation of multiple innate immune
effector molecules and cytokines. These act directly or indirectly to control infection and promote
inflammation in a temporally controlled manner. The most important class of cytokine involved in the
innate response against viral pathogens are the interferons (IFN). These cytokines are responsible for
orchestrating an antiviral state within infected cells, in neighboring cells and in directing immune cell
activation or trafficking to control viral infection.
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3.1. Recognition of DENV and ZIKV by the Innate Immune System
Single-stranded or double-stranded RNAs (ssRNA or dsRNA) produced as by-products of viral
genome replication are commonly recognized PAMPs during Flavivirus infections. For DENV and
ZIKV these RNA PAMPs are mainly recognized by members of the DExD/H box RNA helicase family of
RIG-I like receptors (RLRs) located in the cytoplasm [32]. Detection of viral RNAs can also occur in the
endosomal compartment by the membrane associated Toll-like receptors-3 or 7 (TLR) [31]. Additionally,
both ZIKV and DENV infection results in host mitochondrial DNA (mitoDNA) release that is sensed
by cyclic GMP-AMP synthase (cGAS) and signals through the ER associated intermediate stimulator
of interferon genes (STING) [31,33,34]. Each of these pathways culminates in the phosphorylation and
subsequent activation of the signaling intermediaries TANK-binding kinase 1 (TBK1) and IκB kinase-ε
(IKKε). Following their activation, TBK1 and IKKε phosphorylate IFN-regulatory factors-3/7 (IRF) [31].
Additionally, IKKε phosphorylates the inhibitory subunit of nuclear factor-κB (NF-κB), leading to
inhibitor degradation and subsequent activation of NF-κB [35]. Activated IRF3 and NF-κB translocate
to the nucleus where they act as transcription factors to promote expression mainly of type-I IFNβ and
a small subset of antiviral or proinflammatory genes [36]. Figure 3 summarizes these pathways that
are discussed in more depth below.
Figure 3. Recognition of Zika Virus (ZIKV) and Dengue Virus (DENV) by the innate immune system
and viral evasion of pattern recognition receptor (PRR)-mediated interferons (IFN) production. ZIKV
and DENV infections are sensed by multiple PRRs inside the cell. or pathogen associated molecular
pattern (PAMP) vRNA from the replication stage of the virus lifecycle activates RLRs in the cytosol
(green arrows) or Toll-like receptors (TLRs) in the endosome (gold arrows). Alternatively, both ZIKV
and DENV infection results in release to mitoDNA into the cytoplasm that is sensed by cyclic GMP-AMP
synthase (cGAS), activating stimulator of interferon genes (STING) (purple arrows). Each of these
pathways leads to phosphorylation of kinases TBK1 and IKKε that activate IRF3/7 and NF-κB. These
transcription factors then upregulate the production of type-I IFNβ (blue arrows). However, ZIKV and
DENV have evolved evasion mechanisms (red) to prevent IFN production that target multiple stages
of these pathways.
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3.2. RIG-I Like Receptors
The main drivers of the innate immune response against flaviviruses are the ubiquitously
expressed RLRs, retinoic acid-induced gene I (RIG-I) and melanoma differentiation-associated gene 5
(MDA5) (Figure 3). RIG-I recognizes short 5′-triphosphorylated ssRNA and short dsRNAs whereas
MDA5 is implicated in recognition of longer dsRNA products [9,37,38]. In structure, these PRRs
contain two N-terminal caspase recruitment and activation domains (CARDs) followed by an RNA
helicase domain [9]. PAMP binding causes a conformational change in the receptor that exposes the
CARD interaction domains and facilitates interactions with translocation mediators such as TRIM25
and members of the 14-3-3 family of proteins [35]. The RLR translocase complex is then shuttled
to the mitochondrial associated membranes where the exposed CARD domains interact with the
complimentary CARD domain of signaling intermediate mitochondrial antiviral signaling protein
(MAVS) [35,39]. This interaction triggers MAVS activation leading to subsequent activation of cytosolic
kinases TBK1 and IKKε [31]. Interestingly, CRISPR/Cas9-mediated knockout of RIG-I but not MDA5
led to significantly increased ZIKV replication in A549 cells compared to control, indicating that RIG-I
is the main sensor of ZIKV infection in these cells [40]. Furthermore, knockout of the RLR signaling
intermediate MAVS was shown to enhance ZIKV infection in human placental trophoblast cell lines [41].
Similarly, siRNA mediated knockdown of RIG-I and MDA5 in the Huh7 cell line rendered them highly
susceptible to DENV infection [42]. Collectively these studies demonstrate the importance of the RLRs
in detection of both ZIKV and DENV infection.
3.3. Toll-Like Receptors
In addition to cytosolic PRR activation, viral RNAs can accumulate in the endosomal compartment
where they are recognized by toll-like receptor 3 or 7 (TLR3/7) (Figure 3) [43,44]. TLRs are transmembrane
glycoproteins containing an N-terminal ligand binding ectodomain, a single transmembrane domain
and a C-terminal toll/interleukin-1 receptor (TIR) homology domain located in the cytoplasm [44].
Ligand binding causes receptor dimerization and the recruitment of signal transducers to the TIR
domain [45]. TLR3 is more widely expressed and recognizes dsRNA whereas TLR7 is mainly expressed
in plasmacytoid dendritic cells (DCs) and is activated by ssRNA [9,46]. After ligand binding and
receptor dimerization the cytoplasmic TIR domain of TLR3 interacts with the TIR domain containing
adapter inducing interferon-β protein (TRIF). Next, TRIF interacts with TNF receptor associated
factors (TRAF3/6) and with receptor interacting proteins (RIP1/3). Comparatively, TLR7 activates a
MYD88 dependent pathway that culminates in TRAF6 signaling and subsequent TBK1 and IKKε
activation [9,44]. Evidence that TLR3 plays a significant role in ZIKV recognition is given by siRNA
mediated gene silencing in HFF1 (foreskin fibroblast) cells rendering these cells more permissive to
ZIKV [21]. Interestingly, mice deficient in TLR7 (TLR7-/-) supported equivalent levels of ZIKV replication
compared to wildtype mice [47]. However, in this study ZIKV replication was significantly enhanced
in TLR7-/-/MAVS-/- double-knockout mice compared to wildtype and MAVS-/- single-knockout mice,
indicating a degree of functional redundancy between the TLR and RLR pathways. Additionally, HEK
293 cells exogenously expressing either TLR3 or TLR7 demonstrated elevated levels of downstream
cytokine release following DENV infection [43].
3.4. cGAS-STING
Other than RNA PAMP activation of the innate immune response, DENV and ZIKV infection
also results in the release of mitochondrial DNA (mitoDNA) into the cytoplasm of infected cells
(33, 34). The presence of mitochondrial DNA in the cytoplasm is a hallmark of cellular damage where
it acts as a potent stimulator of apoptosis and innate immune responses (Figure 3) [48]. Release of
mitoDNA during DENV infection results from disruption of normal mitochondrial function. This is
likely mediated by the DENV M protein that disrupts mitochondrial membrane potential [49], while
the DENV NS2B/3 protease also cleaves important mitofusion proteins (MFN1 and MFN2) that are
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important for mitochondrial membrane fusion and homeostasis [50]. ZIKV is also known to impair
mitochondrial function [51], but the molecular mechanisms that drive the release of mitoDNA during
ZIKV infection are unknown. However, it is possible that these mechanisms are similar to those
of DENV. Once in the cytoplasm, mitoDNA can bind directly to the cytosolic DNA sensor cGAS,
resulting in a conformational change allowing cGAS to catalyze the conversion of GTP and ATP to
produce the second messenger cyclic GMP–AMP (cGAMP). Next, cGAMP binds to STING located
in the ER membrane causing oligomerization and translocation to the Golgi, where it activates TBK1
and IKKε [48]. Importantly knockout of cGAS in PMBCs renders these cells more susceptible to ZIKV
infection and limits IFNβ production in infected cells [34]. Moreover, various human cell lines lacking
STING demonstrate enhanced DENV replication in vitro [52].
Each of the above-mentioned pathways stimulates the transcription and translation of type-I IFN
by infected cells. In turn the IFNs are secreted from the cell to orchestrate and amplify a broader
antiviral response both within infected cells and in neighboring cells and tissues.
3.5. Type-I Interferons
In humans, the type-I IFNs are encoded by a cluster of related genes located on chromosome
9 [53]. They include 14 subtypes of IFNα and a single gene encoding each of IFNβ, IFNε, IFNκ, and
IFNω. IFNα and IFNβ are the main IFNs produced downstream of PRR activation. In general, IFNα
expression is dependent on the activation of IRFs (especially IRF7) whereas efficient IFNβ expression
requires both IRF3/7 and NF-κB activation. The nuances of IRF-dependent type-I IFN expression
regulation have been extensively reviewed elsewhere [54]. Collectively, the type-I IFNs are defined by
their ability to signal through the type-I IFN receptor that is composed of two heterodimeric subunits
(IFNAR1 and IFNAR2) and is almost ubiquitously expressed throughout the body [55].
3.6. Signalling from the Type-I IFN Receptor
Once produced in response to detection viral infection, secreted type-I IFN binds to the extracellular
domains of its cognate receptor (IFNAR1/2) expressed on the same cell or on neighboring cells
(Figure 4). Importantly, most cell types respond to type-I IFNs due to the almost ubiquitous expression
of IFNAR1/2 [55,56]. Ligand binding causes hetero-dimerization of the receptor subunits bringing
the intracellular domains of the receptor into close proximity [57]. Each of the IFNAR1 and IFNAR2
intracellular domains are pre-associated with tyrosine kinases that are activated upon receptor
dimerization by close proximity trans-phosphorylation [53]. IFNAR1 is associated with tyrosine kinase
2 (TYK2) and IFNAR2 is associated with janus kinase 1 (JAK1) respectively [58,59]. Once activated
JAK1 and TYK2 phosphorylate the intracellular domains of the IFNAR subunits, allowing docking of
signal transducer and activators (STAT1 and STAT2). Once docked to the receptor, JAK1 and TYK2
phosphorylate STAT1 and STAT2 at tyrosine residues Y701 or Y690 respectively [31]. Phosphorylation
leads to the formation of STAT1/2 heterodimers, nuclear translocation and subsequent complexing
with IRF9 [56]. This hetero-trimeric complex called interferon stimulated gene factor 3 (ISGF3) then
binds to IFN-stimulated response elements (ISRE) in the proximal promoter regions of over 100 ISGs,
up-regulating their transcription and translation [11]. ISGs encode various proteins that carry out
a range of effector or regulatory functions [31]. Effector functions are varied and include inhibition
of viral entry, inhibition of protein synthesis, alterations to cellular metabolism, degradation of viral
proteins or genetic material and inhibition of viral egress [11]. Regulatory ISGs include PRRs and
signaling partners of these pathways as well as immunomodulatory molecules and negative regulators
responsible for controlling immune cell activation and trafficking or returning the cell to homeostasis,
respectively [60].
3.7. Inhibition of ZIKV and DENV Infection by Interferon Stimulated Genes
Type-I IFNs are important in controlling Flavivirus infection through the production of ISGs. These
ISGs play a wide variety of roles in the innate antiviral response and have been extensively reviewed
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elsewhere [11]. Importantly, some ISGs can act directly to inhibit various stages of the ZIKV and DENV
virus lifecycle. Due to the shared aspects of their lifecycles some of these ISGs are similarly effective
against both viruses. Several of these direct acting ISGs are known and their mechanisms of action are
described below.
Figure 4. The molecular interactions of ZIKV and DENV with the type-I IFN pathway. Once produced
and secreted from infected cells type-I IFNs bind to their cognate cell surface receptor, activating
janus kinase-signal transducer and activator (JAK-STAT) signaling (black arrows). This leads to the
phosphorylation of STAT1 and STAT2, their heterodimerzation and subsequent complexing with IRF9
to form the complex ISGF3. ISGF3 then transcriptionally upregulates interferon stimulated genes (ISGs)
that have antiviral effects against ZIKV and DENV. Several stages of the IFN pathway are inhibited by
ZIKV and DENV mediated evasion mechanisms (red).
Two complimentary studies have demonstrated that Interferon Stimulated Gene 15 (ISG15)
protects against ZIKV infection [61,62]. Mature ISG15 is a 15 kDa member of the ubiquitin family of
proteins that plays various roles in the innate immune response that have been extensively reviewed [63].
One of the main functions of ISG15 is the covalent modification of target proteins via ISG15 conjugation
(ISGylation) disrupting target protein localization and protein-protein interactions. Additionally, ISG15
has immune modulatory functions through non-covalent protein interactions and by acting as an
immune cell signaling molecule. One study found that ZIKV infected ISG15-/- mice had increased
severity of retinal lesions and impaired antiviral responses compared to wildtype mice and this led
to lower expression of other ISGs like RIG-I and IFI6 [62]. A follow-up study by the same group
extended these observations to show that ZIKV infection in human primary corneal epithelial cells
(HCEC) induced expression of ISG15 RNA and protein, and that siRNA mediated knockdown of this
expression lead to increased ZIKV infection in these cells [62]. Conversely, heterologous expression of
ISG15 protein was able to ameliorate this effect. Furthermore, this group found that ISG15 expression
was important for both reducing ZIKV entry into host cells, and for inhibiting viral replication once
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inside the cell. Similarly, ISG15 inhibits DENV infection. DENV infection has been shown to upregulate
expression of ISG15 in RAW264.7 cells, and its silencing increased DENV replication in these cells [64].
Furthermore, infection with DENV increased the total amount of ISGylated proteins in the cell,
suggesting a link between the ISG conjugation activity of ISG15 with the observed antiviral effect [64].
Members of the Interferon-Inducible Transmembrane (IFITM) protein family also protect against
both ZIKV and DENV infection. As their name suggests these proteins are found inserted into cellular
membranes, most commonly localizing in late endosomes, and can interfere with fusion of viral and
host membranes following viral entry [65]. Importantly, siRNA mediated knockdown of IFITM1
or 3 was shown to increase ZIKV infection in human cell lines [66]. This effect could be rescued
with overexpressed protein but relied on the protein’s endosomal localization. Consistent with their
localization to endosomal membranes, knockdown of IFITM1 or 3 was shown to impact very early
steps in the viral replication cycle following entry [66]. Likewise ectopically expressed IFITM2 or
IFITM3 have been shown to reduce DENV infection in human cell lines to similar levels to those
observed when treating cells with 100 U/mL IFNα [67]. Like ZIKV, this inhibitory effect was observed
to impact the DENV lifecycle at a step prior to the initial round of viral RNA translation.
Another ISG shown to directly inhibit ZIKV and DENV infection is interferon alpha-inducible
protein 6 (IFI6). IFI6 is a 13 kDa protein that is known to be involved in cell survival and counteracting
viral-mediated apoptosis [68]. Increased expression of IFI6 was shown to reduce ZIKV replication
and prevented ZIKV mediated cell death in the Huh7 (liver origin) cell line [69]. In this study, IFI6
localized to the ER near ZIKV RCs suggesting that it may play a role in inhibiting viral replication or
virion production. Furthermore, this antiviral effect of IFI6 was independent of ZIKV protein stability
or polyprotein processing. Likewise Huh7.5 cells stably transduced with a lentivirus IFI6 expression
vector demonstrated decreased DENV replication compared to an empty vector control [70]. This study
also demonstrated that CRISPR-mediated knockout of endogenous IFI6 expression increased DENV
replication in infected cells.
Furthermore, the virus inhibitory endoplasmic reticulum associated interferon inducible protein
(Viperin) has been shown in multiple studies to reduce ZIKV and DENV replication [71–73]. Viperin is
a 42 kDa protein and as the name suggests is normally associated with ER membranes. Importantly,
Viperin has antiviral effects against a wide range of viruses in both RNA and DNA families [74–76].
The first study to investigate the importance of Viperin in ZIKV infection found that Viperin was
induced in response to ZIKV infection and overexpressed Viperin restricted ZIKV replication in human
cell lines [71]. Additionally, murine embryonic fibroblasts (MEFs) derived from Viperin knockout mice
were more permissive to ZIKV replication compared to wildtype MEFs. Furthermore, the anti-ZIKV
action of Viperin relied on the highly conserved C-terminal end of the protein [74]. A second study
confirmed Viperin’s antiviral effect, finding that Viperin interacted directly with the ZIKV NS3 protein
resulting in its degradation and reduced viral replication [72]. Similarly, DENV inhibition by Viperin
is also dependent on the C-terminal region of the protein and its interaction with the DENV NS3
protein [73].
Aside from these ISGs that are known to inhibit both ZIKV and DENV infection, other direct
acting ISGs have been independently validated for either virus. Future studies may prove these ISGs
are effective against both viruses, or they may reveal virus-specific activity. One of these ISGs is
interferon-inducible factor 16 (IFI16). This ISG has multiple roles in modulating expression of viral
proteins and activating the STING pathway during infection [77]. Overexpressed IFI16 was shown to
reduce infection of both the +ssRNA alphavirus chickungunya virus (CHIKV) and ZIKV in human
skin fibroblasts [78]. No specific mechanism for this effect was investigated. To our knowledge, IFI16
has not been independently validated for antiviral activity against DENV infection. However, the role
of IFI16 in promoting STING activation suggests that this is a strong possibility.
Other ISGs known to inhibit DENV infection are the ArfGAP with dual pleckstrin homology
(PH) domains 2 (ADAP2) protein and the tripartite motif 69 protein (TRIM69). ADAP2 is most highly
expressed in the heart, and skeletal muscle and is known to regulate the ADP ribosylation factor (Arf)
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family of proteins via its GTPase activating protein (GAP) function [79]. Arf proteins are involved
in regulating vesicular trafficking and cytoskeletal organization. Importantly, ectopically expressed
ADAP2 has been demonstrated to restrict DENV infection by inhibiting GAP mediated trafficking
of incoming DENV containing vesicles [80]. TRIM69 mediates protein ubiquitination through its E2
conjugation enzymatic activity. It localizes to the cytoplasm and inside the nucleus of cells [81]. TRIM69
has been shown to directly interact with DENV NS3, resulting in its polyubiquitination and subsequent
degradation to inhibit DENV replication [82]. To our knowledge, the roles of both ADAP2 and TRIM69
in protection against ZIKV infection have not been investigated.
In the context of natural infection, multiple ISGs are expressed in concert and as a result target
many of the stages of DENV and ZIKV replication simultaneously. The combined effects of ISGs to
inhibit ZIKV and DENV infection has applied strong selective pressure on these viruses to evolve
mechanisms to evade detection by the cell or prevent the production of ISGs through blocking the IFN
signaling pathway.
4. Common Strategies Employed by Flaviviruses to Evade the IFN Response
As obligate intracellular pathogens, flaviviruses have evolved many ways to avoid detection by
host intracellular PRRs. For example, the 7-methylguanylate cap that is incorporated on the 5′ end of
the +ssRNA genome by the NS5 MTase domain mimics the appearance of host mRNA (18). 5′ capping
assists host translational initiation factors to bind the viral RNA and prevents RNA degradation by
endonucleases in the cytoplasm [83]. Importantly, 5′ capping also interferes with the recognition of
vRNA as ‘non-self’ by the MDA5 PRR, limiting the production of IFN by infected cells [84]. In addition
to hiding from detection, capping also avoids the antiviral effects of the interferon induced protein
with tetratricopeptide repeats (IFIT) protein family that can bind to and sequester vRNA of uncapped
or cap mutant Flavivirus genomes [85].
The second mechanism commonly used by flaviviruses to avoid detection is the induction of
membrane rearrangements allowing for the formation of the RC as part of the virus lifecycle [86].
As mentioned previously, for flaviviruses these structures are formed from modified ER membranes
by the coordinated action of multiple host and viral proteins. Replication organelles form as a series
of membranes that surround the dsRNA replication intermediate, acting to physically segregate
this potent viral PAMP from detection by cytoplasmic PRRs like RIG-I [87,88]. In addition, these
replication organelles limit the antiviral activity of the ISG encoded MXA protein, likely by blocking
MXA-mediated recognition of the forming viral nucleocapsid [89]. Evidence in support of this theory
is provided in one study comparing DENV to JEV replication where they observed a greater degree of
dsRNA in the cytosol during JEV infection compared to DENV and this correlated to increased IFN
production in JEV infected cells [90]. Ultrastructural analysis of the ZIKV RC shows it to be highly
similar to that of DENV, suggesting their related function [91].
Aside from genome capping and the formation of replication organelles, several flaviviruses
evade IFN production by expression of subgenomic Flavivirus RNA (sfRNA) [92]. Flavivirus sfRNAs
are formed from the incomplete degradation of the viral genome by cellular 5′ to 3′ exonucleases [93].
Specifically, conserved stem-loop or dumbbell RNA structures within the 3′UTR stall exonuclease
activity and result in the production of short RNA sequences [94]. Importantly sfRNAs generated
during ZIKV infection antagonize the activity of both RIG-I and MDA5 [95], although a full mechanism
of action has not been elucidated for this interaction. Likewise, DENV sfRNA inhibits RIG-I mediated
IFN production. This effect is governed by a sequence-specific interaction between DENV sfRNA and
the tripartite motif containing 25 protein (TRIM25) [96]. TRIM25 functions as an RNA binding protein
and a ubiquitin ligase, responsible for the polyubiquitination of activated RIG-I leading to sustained
signal transduction [35].
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4.1. ZIKV-Specific Mechanisms to Evade IFN Responses
In addition to strategies common to all flaviviruses, some evasion mechanisms have been
characterized for ZIKV that may be unique for this virus. These mechanisms prevent ISG production
by interfering with PRR-mediated IFN production, or by directly targeting signaling intermediaries
downstream of the IFNAR1/2 receptor.
One mechanism that limits the production of IFN is mediated by ZIKV NS4A that inhibits RIG-I
and MDA5 signaling and has been demonstrated independently by two groups [41,97]. Collectively
these studies found that ectopically expressed NS4A binds directly to the N-terminal CARD domain
MAVS. This binding competitively inhibited MAVS interaction with activated RIG-I or MDA5, leading
to potent inhibition of downstream type-I IFN production.
ZIKV can also prevent the translocation of activated RIG-I and MDA5 to the mitochondrial
membranes by acting on members of the 14-3-3 protein family. These proteins (14-3-3ε and 14-3-3η)
act as mitochondrial targeting chaperones that are required for translocation of RIG-I and MDA5
respectively, facilitating their interaction with MAVS [98,99]. Importantly, overexpressed ZIKV NS3
protein in HEK 293T cells was able to competitively bind to both 14-3-3ε and 14-3-3η via a conserved
binding motif (64-RLDP-67) [100]. This sequence was found to contain a central negatively charged
Aspartic acid residue (D66) that acted as a phospho-mimetic to compete with RIG-I or MDA5 binding.
Mutation of this binging motif within the full length ZIKV genome attenuated viral replication
compared to wildtype virus in A549 cells [100].
ZIKV can also inhibit the cGAS-STING pathway via the actions of NS1. One study found that
ectopically expressed ZIKV NS1 interacts directly with host de-ubiquitinase USP8 to facilitate the
deubiquitination of caspase-1, increasing its stability [34]. In turn caspase-1 proteolytically cleaves
cGAS, reducing the production of IFN in the cell. Additionally, the ZIKV protease NS2B/3 mediates
STING cleavage. Using exogenous expression in HEK 293T cells it was shown that ZIKV NS2B/3
cleaved human but not mouse STING [101]. This study extended these observations to natural ZIKV
infection in human fibroblasts by detection of STING cleavage products during infection. The reduction
of cGAMP mediated STING activation as a result of ZIKV infection inhibited the production of IFN by
infected cells.
Other NS proteins also contribute to limit IFN production downstream of MAVS, TLR and
cGAS-STING pathways by targeting the shared signaling intermediaries TBK1, IKKε, or IRF3.
Ectopically expressed NS1 and NS4B interact directly with TBK1, preventing TBK1 oligomerization
and phosphorylation mediated activation [102]. Interestingly, another study found that NS1 mediated
TBK1 inhibition was specific to recent outbreak strains that had evolutionarily acquired a 188-Val
substitution mutation [103]. Additionally, overexpressed ZIKV NS5 in HEK 293 cells was demonstrated
to directly interact with IKKε [104]. This direct interaction resulted in reduced IKKε protein
levels and phosphorylation, thereby preventing the activation of IRF3. In another study, NS5
was also shown to inhibit IRF3 activation by direct binding to endogenous IRF3 in studies involving
co-immunoprecipitation of overexpressed NS5 protein [103].
Downstream of the IFN receptor, ZIKV also acts to suppress JAK-STAT signal transduction.
The best characterized of these mechanisms is the ZIKV NS5 mediated degradation of STAT2 protein.
ZIKV NS5 can bind to STAT2 and initiate its degradation in a proteasome dependent manner [105].
Interestingly, this occurs with human but not mouse STAT2 protein, partially explaining the difference
in species adaptation of ZIKV and difficulties associated with infecting IFN competent mice [106].
A separate study found that overexpression of NS5 leading to STAT2 degradation also resulted in
reduced STAT1 phosphorylation in cells overexpressing NS5 [107]. One study also demonstrated that
ZIKV NS2B/3 expression induced the degradation of JAK1 protein in a proteasome-dependent manner
leading to a reduction in IFN mediated ISG expression [102]. In addition to the roles of NS proteins
in inhibition of IFNAR signaling, ZIKV binding to the attachment factor Axl on the cell surface also
inhibits IFN signaling. In a study using microglial cell lines, ZIKV binding was shown to activate the
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C-terminal kinase domain of Axl that in turn acted to negatively regulate the type-I signaling pathway
via induction of SOCS1 protein expression [108].
4.2. DENV-Specific Mechanisms to Evade the IFN Response
Some of the mechanisms that govern DENV-mediated IFN evasion closely reflect those of ZIKV,
demonstrating their close evolutionary relationship. These tend to be evasion strategies mediated by
the more conserved viral proteins, such as the NS3 helicase/protease and NS5 RdRp/MTase. However,
there are also mechanisms that differ entirely in their action and are unique to DENV.
One mechanism preventing the production of IFN by DENV is mediated by NS2B. Overexpressed
DENV NS2B directly interacts with cGAS and causes its degradation by auto-phagolysosomes, reducing
STING-mediated IFN production [33].
Additionally, DENV NS2B/3 proteolytically cleaves human but not mouse STING in a similar
manner to ZIKV [52]. This species-specific cleavage was dependent on the presence of an NS3 cleavage
site in human STING. Mutation of this cleavage site was able to restore DENV-mediated induction
of IFNβ. DENV NS3 also contributes to evasion of IFN by non-proteolytic actions. HEK 293T cells
expressing DENV NS3 demonstrated impaired RIG-I translocation to MAVS in response to Sendai
Virus infection. Like ZIKV, this interaction was also dependent on inhibition of RIG-I binding to 14-3-3ε
via a conserved phospho-mimetic binding motif at the same location within NS3 (64-RxEP-67) [109].
However, the charged residue mimicking the natural phosphorylation site was found to be a Glutamic
acid (Glu66) rather than Aspartic acid residue as was found for the ZIKV NS3 protein. Furthermore,
DENV NS2A and NS4B from multiple DENV serotypes inhibit PRR mediated IFN production via
targeting TBK1 and IRF3. Ectopically expressed DENV NS2A and NS4B were shown to specifically
inhibit TBK1 auto-phosphorylation, and reduced total IRF3 protein levels [110]. Moreover, this
same study found that NS4A from serotype-1 was in addition uniquely able to contribute to TBK1
inhibition [110]. This additional evasion mechanism may contribute to the enhanced virulence of
DENV1. Overexpressed DENV NS2B/3 in HEK 293/TLR3 expressing cells also directly interacts with
the N-terminal Kinase domain of IKKε, inhibiting kinase activity and reducing IFN production [111].
Downstream of IFN receptor activation DENV NS4B blocks STAT1 phosphorylation and nuclear
translocation [112]. DENV NS2A and NS4A were also shown to inhibit ISRE promoter activity
downstream of IFNβ signaling in HEK 293T cells [112]. For NS4B this effect was later found to depend
on the N-terminal signal peptide of the NS4B protein and was enhanced by natural cleavage between
the NS4A-2K-NS4B fragment [113]. For NS2A and NS4A the mechanism driving their IFN evasion
properties has not yet been elucidated. Finally, similar to ZIKV, DENV NS5 mediates human STAT2
degradation in a proteasome dependent manner [114]. This similarity is highlighted by a recent study
that found the specific interacting residues of NS5 and its binding mode with human STAT2 were
highly conserved between ZIKV and DENV [115]. However, in contrast to ZIKV this requires natural
viral processing of NS5 from the polyprotein and is dependent on the ubiquitin ligase UBR4 [116].
Importantly, this intricate web of viral:host molecular interactions for both ZIKV and DENV
means the innate immune system competes with the virus in a race to establish an antiviral state or a
state of immune-suppressed infection. The outcome of this race largely determines the outcome of
natural infection or responses to vaccination. A summary of ZIKV and DENV mediated IFN-evasion
mechanisms is given in Table 1 below.
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Table 1. Summary of virus specific IFN evasion mechanisms for both ZIKV and DENV
ZIKV-Mediated IFN Evasion Mechanisms
Viral Factor Immune Pathway Host Target References
NS4A RLR Binds directly to MAVS [41,97]
NS3 RLR Competitively binds to both 14-3-3ε and 14-3-3η [100]
NS1 cGAS-STING Binds USP8 leading to cGAS cleavage [34]
NS1 and NS4B RLR, TLR, cGAS-STING Interacts with TBK1 [102]
NS5 RLR, TLR, cGAS-STING Interacts with IKKε [104]
NS5 RLR, TLR, cGAS-STING Direct binding to IRF3 [103]
NS5 IFNAR1/2 STAT2 degradation [105]
NS2B/3 IFNAR1/2 JAK1 degradation [102]
Viral attachment IFNAR1/2 Binding to Axl on the cell surface inducing SOCS1 expression [108]
DENV-Mediated IFN Evasion Mechanisms
Viral Factor Immune Pathway Host Target References
NS2B cGAS-STING cGAS degradation [33]
NS2B/3 cGAS-STING STING cleavage [52]
NS3 RLR Competitively binds to both 14-3-3ε [109]
NS2A and NS4B RLR, TLR, cGAS-STING TBK1 inhibition and reduced IRF3 protein levels [110]
NS2B/3 RLR, TLR, cGAS-STING Interacts with IKKε [111]
NS4B IFNAR1/2 Blocking STAT1 phosphorylation [112]
NS5 IFNAR1/2 STAT2 degradation [114]
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5. Exploitation of Enhanced Type-I IFN Responses for Effective Vaccine Development
Aside from directly controlling viral replication, the type-I IFNs also have a significant role in
enhancing adaptive immune responses to viral pathogens. Expression of the type-I receptor on both T
and B cells is required for efficient activation of antibody responses in mice [117,118]. Additionally,
type-I IFN enhances isotype switching via activation of antigen-presenting dendritic cells (DCs) [119].
Because several of the ISGs that are expressed in response to IFNs are chemokines and chemokine
receptors, type-I IFNs also influence immune cell migration and recruitment. For example, in the
presence of type-I interferon, DCs express greater levels of chemokine receptor CCR7 which is important
in the generation of primary immune responses, and greater levels of CXCL10 that are required for
recruitment of Th1 memory lymphocytes [120]. Furthermore, type-I IFN influences cytotoxic T cell
expansion and memory formation [121]. Our understanding of the effect that type-I IFN has on immune
responses to Flavivirus infection have vastly improved due to the development of immune-competent
small animal models. While beyond the scope of this review, small animal models of DENV and ZIKV
infection are of vital importance in pre-clinical testing of the efficacy and safety of vaccine candidates.
Recent advances in this area have been comprehensively reviewed elsewhere [106,122,123].
Collectively, the combined action of type-I IFNs are important to promote efficient immune
activation and therefore IFN or IFN-stimulating adjuvants are often used to enhance vaccine responses.
For example, co-administrated type-I IFN can act as an adjuvant to improve vaccine responses against
influenza in mice [124]. Furthermore, the cationic polysaccharide chitosan is an adjuvant currently
used in vaccines that results in improved Th1 responses compared to other adjuvants like alum salts
that promote mainly Th2 responses [125]. It was recently discovered that chitosan mediated this action
by increasing type-I IFN production, influencing DC maturation and leading to improved antigen
specific Th1 responses following vaccination [126]. Therefore, enhancing type-I IFN responses in
vaccination settings is a proven way to enhance vaccine efficacy, especially where Th1 responses are
important for effective control against viral pathogens [127].
Aside from its potential use as an adjuvant for vaccines, type-I IFN can also be induced naturally
by live-attenuated vaccines leading to long lasting immunity. One example of this is the YF-17D
vaccine licensed for YFV. One study investigating the transcriptomic profile of humans immunized
with YF-17D found that the type-I IFN response was the most highly activated immune signaling
pathway [128]. The type-I IFN response was induced early and transiently, returning to baseline by
day 14. Importantly, the YF-17D vaccine is known to offer highly effective, lifelong protection in most
patients [129].
Mutation of the genetic regions involved in viral evasion of the IFN response has shown promise
in developing new live-attenuated vaccine candidates. One study performing functional profiling on
the Influenza virus genome found a series of mutations within NS1 that conferred IFN hypersensitivity
of these viruses [130]. When these IFN sensitive mutants were introduced into a lethal model of mouse
influenza, the virus generated robust type-I IFN and adaptive immune responses but was highly
attenuated, resulting in a 100% survival rate of infected mice. Inoculation with these IFN sensitive
mutant virus strains protected against homologous and heterologous viral challenge in the lethal
mouse model. Another example of this approach to generate potential live-attenuated vaccines was
recently reported for ZIKV [131]. In this study, a full-length infectious clone of ZIKV was subjected
to site directed mutagenesis focused on residues in ZIKV NS4B that are important for IFN evasion,
namely a C100S mutation. These mutant viruses were propagated in Vero cells that are deficient in
IFN production and used to infect mice. Whereas mice infected with wildtype virus displayed 100%
lethality upon challenge, the C100S mutant virus did not result in significant weight loss or death,
indicating that it was successfully attenuated. During infection, the C100S mutant was found to induce
stronger type-I IFN and antigen specific T cell responses compared to the parent strain. Notably,
vaccination with the C100S mutant protected mice from a lethal ZIKV challenge.
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These examples demonstrate the importance of type-I IFN responses in generating protective
immunity in vaccines. Furthermore, they highlight how the knowledge of viral evasion strategies can
be used for the targeted, rational design of new live-attenuated vaccine candidates.
6. Conclusions
DENV and ZIKV are significant human pathogens that lack appropriate control measures.
The development of safe and effective vaccines is important in the global fight against these pathogens.
The immune response to both viruses is heavily underpinned by an appropriate type-I IFN response.
However, both viruses have developed ways to counteract this aspect of innate immunity to cause
infection and disease in humans. Understanding the molecular interactions of these viruses with
the type-I IFN response is important and may assist in improving current vaccine strategies though
adjuvants or aid in producing future mutant live-attenuated vaccine candidates that are unable to
evade type-I IFN responses.
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